Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis
- PMID: 11570976
- PMCID: PMC56591
- DOI: 10.1186/1471-230x-1-8
Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis
Abstract
Background: Sulfasalazine is a widely used anti-inflammatory agent in the treatment of inflammatory bowel disease and several rheumatological disorders. Although as many as 20% of treated patients may experience reversible, dose-dependent side effects, less frequent but potentially severe, systemic reactions have also been reported.
Case presentation: A severe systemic reaction to sulfasalazine developed in a 21-year old female with rheumatoid arthritis characterized by eosinophilia, granulomatous enteritis and myelotoxicity, cholestatic hepatitis, and seizures. The clinical course and management of this patient are presented as well as a review of the incidence and outcome of severe systemic reactions to sulfasalazine.
Conclusions: Granulomatous myelotoxicity and enteritis developed in a 21 year old female within 3 weeks of initiating sulfasalazine for rheumatoid arthritis. Following a short course of corticosteroids, the patient had resolution of her cholestatic hepatitis, rash, eosinophilia, and gastrointestinal symptoms with no residual manifestations at 7 months follow-up. Although severe reactions to sulfasalazine are rare and unpredictable, practicing physicians should be aware of unusual clinical presentations of toxicity when prescribing sulfasalazine.
Figures


Similar articles
-
Sulfasalazine-induced DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms).Sao Paulo Med J. 2008 Jul;126(4):225-6. doi: 10.1590/s1516-31802008000400006. Sao Paulo Med J. 2008. PMID: 18853032 Free PMC article.
-
A 63-year-old returned traveller with fever, rash, hepatitis and eosinophilia.CMAJ. 2018 Jul 9;190(27):E831-E835. doi: 10.1503/cmaj.171134. CMAJ. 2018. PMID: 29986859 Free PMC article. No abstract available.
-
Drug rash with eosinophilia and systemic symptoms syndrome induced by sulfasalazine.Joint Bone Spine. 2010 Jan;77(1):87-8. doi: 10.1016/j.jbspin.2009.08.003. Epub 2009 Oct 24. Joint Bone Spine. 2010. PMID: 19854669 No abstract available.
-
DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis.Joint Bone Spine. 2005 Jan;72(1):82-5. doi: 10.1016/j.jbspin.2004.06.002. Joint Bone Spine. 2005. PMID: 15681256 Review.
-
Sulfasalazine-induced hepatotoxicity in children with inflammatory bowel disease.J Pediatr Gastroenterol Nutr. 1989 May;8(4):528-32. doi: 10.1097/00005176-198905000-00018. J Pediatr Gastroenterol Nutr. 1989. PMID: 2566669 Review.
Cited by
-
An unusual cause of febrile hepatitis.BMJ Case Rep. 2015 Jun 25;2015:bcr2014205857. doi: 10.1136/bcr-2014-205857. BMJ Case Rep. 2015. PMID: 26113581 Free PMC article.
References
-
- Peppercorn MA. Sulphasalazine pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med. 1984;3:377–386. - PubMed
-
- Das KM. Sulphasalazine therapy in inflammatory bowel disease. Gastroenterol Clin North Amer. 1989;18:1–20. - PubMed
-
- Dougados M, Van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of sponyloarthropathy: a randomized, multi-center, double-blinded, placebo-controlled study. Arthritis Rheum. 1995;38:618–627. - PubMed
-
- Pinals RS, Kaplan SB, Lawson JG, Hepburn B. Sulfasalazine in rheumatoid arthritis. Arthritis Rheum. 1986;29:1427–1434. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical